Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic model

Cell cycle progression in glioblastoma cells is unaffected by pathophysiological levels of hypoxia

(2016) Rosalie Richards et al.   PeerJ

Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer

(2015) C. J. Whatcott et al.   CLINICAL CANCER RESEARCH

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

(2015) M. Konopleva et al.   HAEMATOLOGICA

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

(2015) M. Konopleva et al.   HAEMATOLOGICA

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase III Randomized Trial of Weekly Cisplatin and Irradiation Versus Cisplatin and Tirapazamine and Irradiation in Stages IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited to the Pelvis: A Gynecologic Oncology Group Study

(2014) Paul A. DiSilvestro et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of hypoxia on human cancer cell line chemosensitivity

(2013) Sara Strese et al.   BMC CANCER

Hypoxia Triggers Hedgehog-Mediated Tumor-Stromal Interactions in Pancreatic Cancer

(2013) T. R. Spivak-Kroizman et al.   CANCER RESEARCH

Recent agents targeting HIF-1α for cancer therapy

(2012) Yaozhong Hu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

The role of stroma in pancreatic cancer: diagnostic and therapeutic implications

(2012) Mert Erkan et al.   Nature Reviews Gastroenterology & Hepatology

The reduction of water-soluble tetrazolium salt reagent on the plasma membrane of epidermal keratinocytes is oxygen dependent

(2011) Lynda Weir et al.   ANALYTICAL BIOCHEMISTRY

Long-term exposure to hypoxia inhibits tumor progression of lung cancer in rats and mice

(2011) Lunyin Yu et al.   BMC CANCER

Strategies To Assess Hypoxic/HIF-1-Active Cancer Cells for the Development of Innovative Radiation Therapy

(2011) Chan Joo Yeom et al.   Cancers

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug

(2010) J. Hu et al.   BLOOD

Challenges of drug resistance in the management of pancreatic cancer

(2010) Rizwan Sheikh et al.   Expert Review of Anticancer Therapy

Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group

(2010) Danny Rischin et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine remains the standard of care for pancreatic cancer

(2010) Jordan Berlin et al.   Nature Reviews Clinical Oncology

Selective Killing of Hypoxia-Inducible Factor-1-Active Cells Improves Survival in a Mouse Model of Invasive and Metastatic Pancreatic Cancer

(2009) S. Kizaka-Kondoh et al.   CLINICAL CANCER RESEARCH

HIF2α cooperates with RAS to promote lung tumorigenesis in mice

(2009) William Y. Kim et al.   JOURNAL OF CLINICAL INVESTIGATION

Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity

(2008) R. Sullivan et al.   MOLECULAR CANCER THERAPEUTICS

Nucleoside analogs: molecular mechanisms signaling cell death

(2008) B Ewald et al.   ONCOGENE

Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G1 phase cell cycle arrest

(2008) Sayaka Yoshiba et al.   ORAL ONCOLOGY